Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nele Goeyvaerts

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
British Journal of Clinical Pharmacology|July 2, 2026
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitusNele Goeyvaerts, Per Olsson Gisleskog, Martine Neyens, et al.
Proceedings. Biological Sciences|April 10, 2019
Household members do not contact each other at random: implications for infectious disease modellingNele Goeyvaerts, Eva Santermans, Gail Potter, et al.
Clinical Trials (London, England)|January 16, 2016
Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challengesAn Vandebosch, Robin Mogg, Nele Goeyvaerts, et al.
Plos One|July 21, 2015
Animal Ownership and Touching Enrich the Context of Social Contacts Relevant to the Spread of Human Infectious DiseasesYimer Wasihun Kifle, Nele Goeyvaerts, Kim Van Kerckhove, et al.
Plos Computational Biology|December 6, 2023
Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamicsClare P McCormack, Olivia Goethals, Nele Goeyvaerts, et al.
Cancer Chemotherapy and Pharmacology|January 3, 2022
Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinomaAnne-Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, et al.
Clinical Pharmacology in Drug Development|July 15, 2025
Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ-1802) in Healthy Adult ParticipantsThomas N Kakuda, Nicole Harasym, Annemie Buelens, et al.
Clinical Pharmacology and Therapeutics|May 15, 2025
Population Pharmacokinetics of siRNA JNJ-73763989 in Healthy Participants and Patients With Chronic Hepatitis BTetsuro Ogawa, Nele Goeyvaerts, Thomas N Kakuda, et al.
Journal of the Royal Society, Interface|June 10, 2026
Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infectionClare McCormack, Olivia Goethals, Nele Goeyvaerts, et al.
Antiviral Therapy|January 24, 2023
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participantsLiviawati S Wu, Yue Hu, Edward J Gane, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|July 2, 2026
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitusNele Goeyvaerts, Per Olsson Gisleskog, Martine Neyens, et al.
Proceedings. Biological Sciences|April 10, 2019
Household members do not contact each other at random: implications for infectious disease modellingNele Goeyvaerts, Eva Santermans, Gail Potter, et al.
Clinical Trials (London, England)|January 16, 2016
Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challengesAn Vandebosch, Robin Mogg, Nele Goeyvaerts, et al.
Plos One|July 21, 2015
Animal Ownership and Touching Enrich the Context of Social Contacts Relevant to the Spread of Human Infectious DiseasesYimer Wasihun Kifle, Nele Goeyvaerts, Kim Van Kerckhove, et al.
Plos Computational Biology|December 6, 2023
Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamicsClare P McCormack, Olivia Goethals, Nele Goeyvaerts, et al.
Cancer Chemotherapy and Pharmacology|January 3, 2022
Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinomaAnne-Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, et al.
Clinical Pharmacology in Drug Development|July 15, 2025
Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ-1802) in Healthy Adult ParticipantsThomas N Kakuda, Nicole Harasym, Annemie Buelens, et al.
Clinical Pharmacology and Therapeutics|May 15, 2025
Population Pharmacokinetics of siRNA JNJ-73763989 in Healthy Participants and Patients With Chronic Hepatitis BTetsuro Ogawa, Nele Goeyvaerts, Thomas N Kakuda, et al.
Journal of the Royal Society, Interface|June 10, 2026
Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infectionClare McCormack, Olivia Goethals, Nele Goeyvaerts, et al.
Antiviral Therapy|January 24, 2023
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participantsLiviawati S Wu, Yue Hu, Edward J Gane, et al.
Pageof 3